Exenatide extended-release for injectable suspension (Bydureon, Amylin) has been approved by the FDA as a once-weekly treatment for type 2 diabetes. The glucagon-like peptide-1 receptor agonist is indicated as an adjunct to diet and exercise to improve glycemic control in adults.
Source: Amylin.
